NEW YORK — Genedrive said on Friday that it has received CE marking under the EU's In Vitro Diagnostic Medical Device Regulation (IVDR) for its point-of-care CYP2C19 ID Kit genotyping platform, which ...

The envisioned flow cytometry test will help to predict patient response to immunotherapies for five cancer indications.

The London-based firm will provide its CIZ1B lung cancer test and DEX-G2 gastric cancer test for use in Doctors Hospital in the Cayman Islands.

The companies will develop and commercialize diagnostic tools to help clinicians determine which patients would benefit from precision medicine treatments.

The company's flagship assay uses whole-genome sequencing to identify patients with high-risk multiple myeloma and determine which patients won't respond to therapies.

The firm touted new assays, provided an update on its nanopore sequencer, and offered insights into upcoming pipeline ...

The firm's shares rose to $62.17 at the close of Tuesday's trading on news that TPG and Blackstone had offered to take the firm private.

The firm raised its full-year revenue guidance on expectations of growth in the range of 3 to 5 percent but it maintained its full-year EPS guidance.

Investors and consultants in the space said that they have seen rising enthusiasm among investors as recent funding rounds ...

According to the FDA, the tubes are not being produced in conformity with good manufacturing practice and have led to false positive lead test results.

The firm presented data at AACR that showed the test had high accuracy when distinguishing ovarian cancer at early stages.

During a fireside chat at the RBC Healthcare Conference, Bio-Rad's CFO Roop Lakkaraju confirmed the firm's prior guide for 130 basis points of net tariff impact, which Connor McNamera, RBC's moderator ...